WO2003028727A9 - 3-`hydroxy- (-4-trifluoromethylphenyl) -methyl!-7-spirocyclobutyl-5,6,7,8- tetrahydrochinolin-5-ol-derivate und ihre verwendung als cholesterin-ester-transfer-protein (cetp) - inhibitoren - Google Patents
3-`hydroxy- (-4-trifluoromethylphenyl) -methyl!-7-spirocyclobutyl-5,6,7,8- tetrahydrochinolin-5-ol-derivate und ihre verwendung als cholesterin-ester-transfer-protein (cetp) - inhibitorenInfo
- Publication number
- WO2003028727A9 WO2003028727A9 PCT/EP2002/010444 EP0210444W WO03028727A9 WO 2003028727 A9 WO2003028727 A9 WO 2003028727A9 EP 0210444 W EP0210444 W EP 0210444W WO 03028727 A9 WO03028727 A9 WO 03028727A9
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compounds
- mmol
- spirocyclobutyl
- formula
- hydroxy
- Prior art date
Links
- 0 *=C(c(cc1)ccc1C(C(C1c(cc2)ccc2F)=C(C2CCCC2)NC(CC2(CCC2)C2)=C1C2=O)=O)F Chemical compound *=C(c(cc1)ccc1C(C(C1c(cc2)ccc2F)=C(C2CCCC2)NC(CC2(CCC2)C2)=C1C2=O)=O)F 0.000 description 8
- NQZLLORIQXURRV-UHFFFAOYSA-N CCCc(c(C(C1=CCC(C)(C(F)(F)F)C=C1)=O)c(C1CCCC1)nc1CC2C3CCCC2)c1C3=O Chemical compound CCCc(c(C(C1=CCC(C)(C(F)(F)F)C=C1)=O)c(C1CCCC1)nc1CC2C3CCCC2)c1C3=O NQZLLORIQXURRV-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
- C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
- C07D221/20—Spiro-condensed ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
Definitions
- the present invention relates to substituted tetrahydroquinolines, processes for their preparation and their use in medicaments.
- Tetrahydroquinolines with pharmacological activity are known from EP-A-818 448, WO 99/15504 and WO 99/1421.
- Substituted tetrahydronaphthalenes with pharmacological activity are known from WO 99/14174.
- the present invention relates to novel tetrahydroquinolines of the general formula (I)
- tetrahydroquinolines according to the invention can also be present in the form of their salts.
- salts with organic or inorganic bases or acids may be mentioned here.
- physiologically acceptable salts are preferred.
- Physiologically acceptable salts of the compounds according to the invention may be salts of the substances according to the invention with mineral acids, carboxylic acids or sulfonic acids. Particularly preferred are e.g. Salts with hydrochloric acid,
- Hydrobromic acid sulfuric acid, phosphoric acid, methanesulfonic acid, ethanesulfonic acid, toluenesulfonic acid, benzenesulfonic acid, naphthalenedisulfonic acid, acetic acid, propionic acid, lactic acid, tartaric acid, citric acid, fumaric acid, maleic acid or benzoic acid.
- Physiologically acceptable salts may also be metal or ammonium salts of the compounds of the invention which have a free carboxyl group. Particularly preferred are e.g. Sodium, potassium, magnesium or calcium salts, and ammonium salts derived from ammonia, or organic amines such as ethylamine, di- or. Triethylamine, di- or
- Triethanolamine dicyclohexylamine, dimethylaminoethanol, arginine, lysine, ethylenediamine or 2-phenylethylamine.
- the compounds according to the invention can be prepared in stereoisomeric forms which are either like image and mirror image (enantiomers) or which are not like image and Mirror image (diastereomers) behavior, exist.
- the invention relates to both the enantiomers or diastereomers and their respective mixtures. These mixtures of the enantiomers and diastereomers can be separated in a known manner in the stereoisomerically uniform components.
- R is a hydroxy-protecting group, preferably a radical of the formula -SiR 2 R 3 R 4 ,
- R 2 and R 4 are identical or different and denote C 1 -C 4 -alkyl
- R 1, A and B have the meanings given above,
- Suitable solvents for all processes are ethers such as diethyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether or hydrocarbons such as benzene, toluene, xylene, hexane, cyclohexane or petroleum fractions, or halogenated hydrocarbons such as dichloromethane, trichloromethane, tetrachloromethane, dichloroethylene, trichlorethylene or chlorobenzene , or ethyl acetate, or triethylamine, pyridine, dimethyl sulfoxide, dimethylformamide, hexamethylphosphoric triamide, acetonitrile, acetone or nitromethane. It is also possible to use mixtures of said solvents. Preference is given to dichloromethane.
- Suitable bases for the individual steps are the usual strongly basic compounds. These preferably include organolithium compounds such as, for example, n-butyllithium, sec-butyllithium, tert-butyllithium or phenyllithium, or amides such as lithium diisopropylamide, sodium amide or potassium amide, or lithium hexamethylsilylamide, or alkali metal hydrides such as sodium hydride or potassium hydride. Particular preference is given to n-butyllithium, sodium hydride or
- Lithium diisopropylamide used.
- the reductions are generally carried out with reducing agents, preferably those suitable for the reduction of ketones to hydroxy compounds. Particularly suitable here is the reduction with metal hydrides or complex metal hydrides in inert solvents, if appropriate in the presence of a trialkylborane.
- the reduction is preferably carried out with complex metal hydrides such as, for example, lithium borohydride, sodium borohydride, potassium borohydride, zinc borohydride, lithium trialkylhydridoboranate, diisobutylaluminum hydride or lithium aluminum hydride. Most preferably, the reduction is carried out with diisobutylaluminum hydride and sodium borohydride.
- the reducing agent is generally used in an amount of from 1 mol to 6 mol, preferably from 1 mol to 4 mol, based on 1 mol of the compounds to be reduced.
- the reduction generally proceeds in a temperature range from -78 ° C to + 50 ° C, preferably from -78 ° C to 0 ° C in the case of DIBAH, 0 ° C to room temperature in the case of NaBFLj, more preferably at -78 ° C, in each case depending on the choice of the reducing agent and solvents.
- the reduction generally proceeds at normal pressure, but it is also possible to work at elevated or reduced pressure.
- the hydrogenation is carried out by conventional methods with hydrogen in the presence of noble metal catalysts, such as Pd / C, Pt / C or Raney nickel in one of the solvents listed above, preferably in alcohols such as methanol, ethanol or propanol, in a temperature range of -20 ° C to + 100 ° C, preferably from 0 ° C to + 50 ° C, at atmospheric pressure or overpressure.
- noble metal catalysts such as Pd / C, Pt / C or Raney nickel in one of the solvents listed above, preferably in alcohols such as methanol, ethanol or propanol, in a temperature range of -20 ° C to + 100 ° C, preferably from 0 ° C to + 50 ° C, at atmospheric pressure or overpressure.
- the deprotection is generally carried out in one of the abovementioned alcohols and THF, preferably methanol / THF in the presence of hydrochloric acid in a temperature range from 0 ° C to 50 ° C, preferably at room temperature, and atmospheric pressure.
- the deprotection with tetrabutylammonium fluoride (TBAF) in THF is preferred.
- Hydroxy-protecting group within the scope of the definition given above generally represents a protective group from the series: trimethylsilyl, triisopropylsilyl, tert-butyl-dimethylsilyl, benzyl, benzyloxycarbonyl, 2-nitrobenzyl, 4-nitrobenzyl, tert-butyloxycarbonyl, allyloxycarbonyl, 4-methoxybenzyl , 4-methoxybenzyloxycarbonyl, tetrahydropyranyl, formyl, acetyl, trichloroacetyl, 2,2,2-trichloroethoxycarbonyl, methoxyethoxymethyl, [2- (trimethylsilyl) ethoxy] methyl, benzoyl, 4-methylbenzoyl, 4-nitrobenzoyl, 4 Fluorobenzoyl, 4-chlorobenzoyl or 4-methoxybenzoyl.
- Suitable solvents for the individual steps are ethers such as diethyl ether, dioxane, tetrahydrofuran, glycol dimethyl ether, diisopropyl ether or hydrocarbons such as benzene, toluene, xylene, hexane, cyclohexane or petroleum fractions, or halogenated hydrocarbons such as dichloromethane, trichloromethane, carbon tetrachloride, dichloroethylene, trichlorethylene or chlorobenzene. It is also possible mixtures of the above
- Suitable oxidizing agents for the preparation of the compounds of the general formula (III) are, for example, nitric acid, cerium (IV) ammonium nitrate, 2,3-dichloro-5,6-dicyano-benzoquinone, pyridinium chlorochromate (PCC), pyridinium chlorochromate on basic aluminum oxide, osmium tetroxide and manganese dioxide. Preference is given to manganese dioxide and nitric acid.
- the oxidation takes place in one of the abovementioned chlorinated hydrocarbons and water.
- Preferred are dichloromethane and water.
- the oxidizing agent is used in an amount of from 1 mol to 10 mol, preferably from 2 mol to 5 mol, based on 1 mol of the compounds of the general formula (II).
- the oxidation generally proceeds at a temperature of -50 ° C to + 100 ° C, preferably from 0 ° C to room temperature.
- the oxidation generally proceeds at atmospheric pressure. But it is also possible to carry out the oxidation at elevated or reduced pressure.
- the asymmetric reduction to the compounds of general formula (IN) is generally carried out in one of the abovementioned ethers or toluene, preferably tetrahydrofuran and toluene.
- the reduction is generally carried out with enantiomerically pure lR, 2S-aminoindanol and borane complexes such as BH 3 x THF, BH 3 x DMS and BH 3 x (C 2 H 5) 2 NC 6 H. 5
- the system is borandiethylaniline / IR, 2S-aminoindanol.
- the reducing agent is generally used in an amount of from 1 mol to 6 mol, preferably from 1 mol to 4 mol, based on 1 mol of the compounds to be reduced.
- the reduction generally proceeds at a temperature of from -78 ° C to + 50 ° C, preferably from 0 ° C to 30 ° C.
- the reduction generally proceeds at atmospheric pressure, but it is also possible to work at elevated or reduced pressure.
- Hydrocarbons preferably in toluene in the presence of lutidine in a temperature range from -20 ° C to + 50 ° C, preferably from -5 ° C to room temperature and atmospheric pressure.
- Reagents for introducing the silyl protective group are generally tert-butyldimethylsilyl chloride or tert-butyldimethylsilyl trifluoromethanesulfonate. Preference is given to tert-butyldimethylsilyltrifluoromethanesulfonate.
- the reduction for the preparation of the compounds of the general formula (VI) is generally carried out using customary reducing agents, preferably those suitable for the reduction of ketones to hydroxy compounds. Particularly suitable here is the reduction with metal hydrides or complex metal hydrides in inert solvents, if appropriate in the presence of a trialkyl borane.
- the reduction is preferably carried out with complex metal hydrides such as, for example, lithium borohydride, sodium borohydride, potassium borohydride, zinc borohydride, lithium trialkyl hydridoboranate, diisobutylaluminum hydride, sodium bis (2-methoxyethoxy) dihy- droaluminat or lithium aluminum hydride performed. Most preferably, the reduction is carried out with sodium bis (2-methoxyethoxy) dihydroaluminate.
- the reducing agent is generally used in an amount of from 1 mol to 6 mol, preferably from 1 mol to 3 mol, based on 1 mol of the compounds to be reduced.
- the reduction generally proceeds at a temperature of -20 ° C to + 110 ° C, preferably from 0 ° C to room temperature.
- the reduction generally proceeds at normal pressure, but it is also possible to work at elevated or reduced pressure.
- Suitable solvents for the preparation of the compounds of general formula (II) are the ethers or alcohols listed above. Preference is given to diisopropyl ether.
- Suitable acids for the preparation of the compounds of general formula (II) are generally organic carboxylic acids and inorganic acids, such as oxalic acid, maleic acid, phosphoric acid, fumaric acid and trifluoroacetic acid. Preference is given to trifluoroacetic acid.
- the acid is generally preferred in an amount of 0.1 mol to 5 mol
- the reaction is generally carried out at atmospheric pressure. But it is also possible to carry out the reaction at elevated or reduced pressure.
- the reaction generally occurs at the reflux temperature of the particular solvent.
- the compounds of the general formula (I) according to the invention have valuable pharmacological properties and can be used for the prevention and treatment of diseases.
- the compounds according to the invention are highly effective inhibitors of cholesterol ester transfer protein (CETP) and stimulate reverse cholesterol transport.
- CETP cholesterol ester transfer protein
- the active compounds according to the invention reduce LDL (low density lipoprotein) in the blood while increasing HDL cholesterol (high density lipoprotein). They can therefore be used for the treatment and prevention of hypolipoproteinemia, dyslipidaemias, hypertriglyceridemias, hyperlipidemias or arteriosclerosis.
- the active compounds according to the invention can also be used for
- the active compounds according to the invention are furthermore suitable for the treatment and prevention of strokes (Stroke) and Alzheimer's disease.
- the active compounds according to the invention open up a further treatment alternative and represent an enrichment of pharmacy.
- the compounds according to the invention show an improved spectrum of activity. They are preferably characterized by high specificity, good tolerability and fewer side effects, especially in the cardiovascular area.
- An advantage of the compounds according to the invention, in addition to their high activity, is in particular a reduced deposition behavior in adipose tissue.
- the pharmacological effect can be determined by means of known CETP inhibition tests.
- the new active compounds may be used alone and, if required, also in combination with other active substances preferably from the group CETP inhibitors, antidiabetics, antioxidants, cytostatics, calcium antagonists, antihypertensive agents, thyromimetics, inhibitors of HMG-CoA reductase, inhibitors of HMG-CoA
- Reductase gene expression, squalene synthesis inhibitors, ACAT inhibitors, bleed-promoting agents, antiplatelet agents, anticoagulants, angiotensin II receptor antagonists, cholesterol absorption inhibitors, MTP inhibitors, aldose reductase inhibitors, fibrates, niacin, anorectics, lipase - Inhibitors and PPAR agonists are administered.
- Glucosidase and / or amylase inhibitors in the context of the invention are, for example, acarbose, adiposine, voglibose, miglitol, emiglitate,
- MDL-25637 camiglibose (MDL-73945)
- tendamistate tendamistate
- AI-3688 trestatin
- pradimicin-Q salbostatin
- compositions of the present invention with cholesterol lowering statins, HDL elevating principles, bile acid absorption relaxants, cholesterol absorption blockers, vasoactive principles or ApoB lowering principles to treat dyslipidemias, combined hyperlipidemias, hypercholesterolemias or hypertriglyceridemias.
- the said combinations are also useful for the primary or secondary prevention of coronary heart disease (e.g., myocardial infarction).
- coronary heart disease e.g., myocardial infarction
- Statins in the context of the invention are, for example, lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin, rosuvastatin and cerivastatin.
- ApoB lowering agents are, for example, MTP inhibitors
- vascular principles may include, but are not limited to, adhesion inhibitors, chemokine receptor
- Antagonists include cell proliferation inhibitors or dilated active substances.
- statins or ApoB inhibitors with one of the abovementioned compounds of the general formula (I) according to the invention is preferred.
- the active substances can act systemically and / or locally.
- they may be applied in a suitable manner, such as, for example, orally, parenterally, pulmonarily, nasally, sublingually, lingually, buccally, rectally, transdermally, conjunctivally, otically or as an implant.
- the active ingredient can be administered in suitable administration forms.
- Tablets non-coated and coated tablets, for example enteric-coated tablets or film-coated tablets
- capsules dragees, granules, pellets, powders, emulsions, suspensions and solutions.
- Parenteral administration can be carried out bypassing a resorption step (intravenously, intraarterially, intracardially, intraspinally or intralumbarly) or using absorption (intramuscular, subcutaneous, intracutaneous, percutaneous, or intraperitoneal).
- a resorption step intravenously, intraarterially, intracardially, intraspinally or intralumbarly
- absorption intramuscular, subcutaneous, intracutaneous, percutaneous, or intraperitoneal.
- parenteral administration are suitable as application forms u.a. Injection and infusion preparations in the form of solutions, suspensions, emulsions, lyophilisates and sterile powders.
- Inhalant medicines including powder inhalers, nebulizers
- nasal drops / solutions, sprays lingual, sublingual or buccal tablets or capsules to be applied, suppositories, ear and eye preparations, vaginal capsules, aqueous suspensions (lotions, shake mixtures), lipophilic suspensions, ointments, creams, milk, pastes, powdered powders or implants.
- the new active ingredients are used in the manufacture of medicines, in particular for the manufacture of medicaments for the prevention and treatment of the abovementioned diseases.
- Medicaments are prepared in a known manner by converting the compounds according to the invention into the customary formulations, such as tablets, dragees, pills, granules, aerosols, syrups, emulsions, suspensions and solutions. This is done using inert nontoxic, pharmaceutically acceptable
- Excipients include u.a. Carriers (eg microcrystalline cellulose), solvents (eg liquid polyethylene glycols), emulsifiers (eg sodium dodecyl sulfate), dispersants (eg polyvinylpyrrolidone), synthetic and natural biopolymers (eg albumin), stabilizers (eg antioxidants like ascorbic acid), dyes (eg inorganic pigments
- Carriers eg microcrystalline cellulose
- solvents eg liquid polyethylene glycols
- emulsifiers eg sodium dodecyl sulfate
- dispersants eg polyvinylpyrrolidone
- synthetic and natural biopolymers eg albumin
- stabilizers eg antioxidants like ascorbic acid
- dyes eg inorganic pigments
- the therapeutically active compound should be present in each case in a concentration of about 0.5 to 90 wt .-% of the total mixture, ie in amounts sufficient to equal the
- the formulations are prepared, for example, by stretching the active ingredients with solvents and / or carriers, optionally using emulsifiers and / or dispersants, e.g. in the case of using water as a diluent, organic solvents may optionally be used as auxiliary solvents.
- Intravenous, parenteral, perlingual and in particular oral administration are preferred.
- solutions of the active ingredient may be added
- Quantities may be recommended to distribute them in several single doses throughout the day.
- Example 4 678 mg (5.46 mmol) reacted 4-fluorobenzaldehyde and 834 mg (5.46 mmol) spiro [3.5] nonane-6,8-dione.
- Example 9 190 mg (0.38 mmol) from Example 9 are reacted analogously to the instructions of the compound from Example 21.
- Example 12 596 mg (1.23 mmol) from Example 12 are reacted analogously to the instructions of the compound from Example 21.
- Example 11 220 mg (0.43 mmol) from Example 11 are reacted analogously to the instructions of the compound from Example 21.
- Example 10 450 mg (0.93 mmol) from Example 10 are reacted analogously to the instructions of the compound from Example 21.
- Example 13 500 mg (0.98 mmol) from Example 13 are reacted analogously to the instructions of the compound from Example 21.
- Example 14 417 mg (0.86 mmol) from Example 14 are reacted analogously to the instructions of the compound from Example 21.
- Example 15 320 mg (0.63 mmol) from Example 15 are reacted analogously to the instructions of the compound from Example 21.
- Example 16 295 mg (0.63 mmol) from Example 16 are reacted analogously to the instructions of the compound from Example 21.
- Example 17 300 mg (0.60 mmol) from Example 17 are reacted analogously to the instructions of the compound from Example 21.
- Example 18 1.1 g (2.27 mmol) from Example 18 are reacted analogously to the instructions of the compound from Example 21.
- Example 19 198 mg (0.42 mmol) from Example 19 are reacted analogously to the instructions of the compound from Example 21.
- Example 20 187 mg (0.40 mmol) from Example 20 are reacted analogously to the instructions of the compound from Example 21.
- Example 23 254 mg (0.53 mmol) from Example 23 are reacted analogously to the instructions of the compound from Example 36.
- Example 24 66 mg (0.13 mmol) from Example 24 are reacted analogously to the instructions of the compound from Example 36.
- Example 25 550 mg (1.14 mmol) from Example 25 are prepared analogously to the instructions of the Bond implemented from Example 36.
- Example 26 230 mg (0.45 mmol) from Example 26 are reacted analogously to the instructions of the compound from Example 36.
- Example 27 400 mg (0.83 mmol) from Example 27 are reacted analogously to the instructions of the compound from Example 36.
- Example 28 100 mg (0.20 mmol) from Example 28 are reacted analogously to the instructions of the compound from Example 36.
- Example 29 590 mg (1.22 mmol) from Example 29 are reacted analogously to the instructions of the compound from Example 36.
- Example 30 300 mg (0.59 mmol) from Example 30 are reacted analogously to the instructions of the compound from Example 36.
- Example 31 285 mg (0.61 mmol) from Example 31 are reacted analogously to the instructions of the compound from Example 36.
- Example 32 200 mg (0.4 mmol) from Example 32 are reacted analogously to the instructions of the compound from Example 36.
- Example 33 372 mg (0.77 mmol) from Example 33 are reacted analogously to the instructions of the compound from Example 36.
- Example 34 127 g (0.27 mmol) from Example 34 are reacted analogously to the instructions of the compound from Example 36.
- Example 35 116 mg (0.25 mmol) from Example 35 are reacted analogously to the instructions of the compound from Example 36.
- Example 36 571 mg (1.15 mmol, 1 eq) from Example 36 are initially charged in 50 ml of THF at 0 ° C, then 1.26 ml (1.26 mmol, 1.1 eq.) Of a one molar solution of Lithium aluminum hydride in THF and the solution is stirred for one hour at 0 ° C and for 18 hours overnight. Then 1 ml of methanol is added, the solution is concentrated by evaporation and chromatographed (silica gel, mobile phase cyclohexane / ethyl acetate mixtures).
- Example 38 233 mg (0.49 mmol) from Example 38 are reacted analogously to the instructions of the compound from Example 51/52.
- Example 39 58 mg (0.11 mmol) from Example 39 are reacted analogously to the instructions of the compound from Example 51/52.
- Example 40 546 mg (1.12 mmol) from Example 40 are reacted analogously to the instructions of the compound from Example 51/52.
- Example 41 180 mg (0.35 mmol) from Example 41 are reacted analogously to the instructions of the compound from Example 51/52.
- IH, rotamer 2 3.2 (m, IH), 3.3 (d, IH rotamer 1), 3.3 (d, IH rotamer 2), 4.6 (t / d, IH rotamer 1) , 4.7 (t / d, IH rotamer 2), 5.8 (d, IH rotamer 1), 5.8 (d, IH rotamer i 2), 6.9 (m, IH rotamer 1), 7, 0 (m, IH rotamer 2), 7, 1 (m, IH rotamer 1), 7.2 (m,
- Example 42 380 mg (0.78 mmol) from Example 42 are reacted analogously to the instructions of the compound from Example 51/52.
- Example 43 80 mg (0.16 mmol) from Example 43 are reacted analogously to the instructions of the compound from Example 51/52.
- Example 44 345 mg (0.71 mmol) from Example 44 are reacted analogously to the instructions of the compound from Example 51/52.
- Example 45 774 mg (0.51 mmol) from Example 45 are reacted analogously to the instructions of the compound from Example 51/52.
- Example 46 237 mg (0.50 mmol) from Example 46 are reacted analogously to the instructions of the compound from Example 51/52.
- Example 47 154 mg (0.31 mmol) from Example 47 are reacted analogously to the instructions of the compound from Example 51/52.
- Example 48 346 mg (0.72 mmol) from Example 48 are reacted analogously to the instructions of the compound from Example 51/52.
- Example 49 83 mg (0.18 mmol) from Example 49 are reacted analogously to the instructions of the compound from Example 51/52.
- Example 50 109 mg (0.23 mmol) from Example 50 are reacted analogously to the instructions of the compound from Example 51/52.
- keto-alcohol from Example 37 735 mg (1.40 mmol) of keto-alcohol from Example 37 are initially charged under argon in toluene (5 ml, pa, dried over molecular sieve), 600 mg (5.60 mmol) of 2,6-lutidine are added at RT and the mixture is chromatographed. Cooled to 16 ° C. 740 mg (2.81 mmol) of tert-butyldimethylsilyl trifluoromethanesulfonate in
- Toluene (1.5 ml) was added dropwise and rinsed twice with 0.25 ml of toluene. After 15 min, the mixture is warmed to 0 ° C. and the reaction mixture is stirred at this temperature for 80 min.
- 0.1N hydrochloric acid (20 ml) is added and, after warming to RT, shaken out with ethyl acetate. The aqueous phase is extracted three more times with ethyl acetate, the combined organic phases washed with a 1: 1 mixture of sodium bicarbonate solution and saturated brine and this aq. Phase extracted again with ethyl acetate.
- Reaction mixture is stirred for 1.5 h with ice cooling, 45 min with slow heating to 13 ° C and 50 min without cooling.
- To stop the reaction is cooled again to 0 ° C and methanol (1 ml) was added.
- methanol (1 ml) was added.
- the aq. Phase is extracted three more times with ethyl acetate, the combined org. Phases dried over sodium sulfate, filtered and concentrated in vacuo.
- the residue (878 mg) is purified by chromatography on silica gel with ethyl acetate / petroleum ether 1:20.
- Example 79 30 mg (0.05 mmol) from Example 79 are initially charged under argon and added to the TBAF
- CETP is recovered from human plasma by differential centrifugation and column chromatography in partially purified form and used for testing.
- human plasma is adjusted with NaBr to a density of 1.21 g per ml and centrifuged for 18 h at 50,000 rpm at 4 ° C.
- the bottom fraction (d> 1.21 g / ml) is applied to a Sephadex ® Phenyl-Sepharose 4B (Fa. Pharmacia) column, washed with 0.15 m NaCl / 0.001 m TrisHCl pH 7.4 and then with distilled water. Water elutes.
- the CETP-active fractions are pooled, dialyzed against 50 mM Na acetate pH 4.5 and applied to a CM-Sepharose ® (Fa. Pharmacia) column. With a linear gradient (0-1 M NaCl) is then eluted.
- the pooled CETP fractions are dialysed against 10 mM Tris-HCl pH 7.4, then further purified by chromatography on a Mono Q ® column (Fa. Pharmacia).
- the suspension is then sonicated under N 2 atmosphere for 30 minutes in Braukson ultrasound bath at about 50 watts, the temperature was kept at about 20 ° C.
- the acceptor liposomes are obtained analogously from 86 mg cholesteryl oleate, 20 mg triolein and 100 mg phosphatidylcholine dissolved in 1.2 ml dioxane and 114 ml of the above buffer by sonicating for 30 minutes at 50 watts (20 ° C.).
- test mix consisting of 1 part of the above buffer, 1 part of donor liposomes and 2 parts of acceptor liposomes are used.
- test mixture 80 .mu.l of test mixture are obtained with 1 - 3 .mu.g enriched CETP fraction, obtained by hydrophobic chromatography from human plasma, and 2 .mu.l of the investigated
- the change in fluorescence at 485/535 nm is a measure of the CE transfer, the inhibition of the transfer compared to the control batch without substance is determined.
- the following table gives the results for the examples:
- the batch is then adjusted to density 1.21 with NaBr and centrifuged in the Ty 65 rotor at 50,000 rpm for 18 h at 20 ° C.
- the isolated, labeled lipoprotein fraction is adjusted to a density of 1.26 with NaBr.
- 4 ml of this solution are covered in centrifuge tubes (SW 40 rotor) with 4 ml of a solution of density 1.21 and 4.5 ml of a solution of 1.063 (density solutions of PDB buffer and NaBr) and then 24 h at 38,000 rpm and 20 ° C in the SW
- the intermediate layer containing the labeled HDL between density 1.063 and 1.21 is dialysed against 3 * 100 volume of PDB buffer at 4 ° C.
- the retentate contains radioactively labeled H-CE-HDL, which is used for testing at approximately 5x10 cmp per ml.
- the reaction is stopped by addition of streptavidin-SPA®beads (Amersham) and the radioactivity transferred determined directly in the liquid scintillation counter.
- SPA-streptavidin bead solution (TRKQ 7005) are added, 1 h while shaking further incubated and then measured in scintillation counter.
- the controls are incubations with 10 ⁇ l buffer, 10 ⁇ l CETP at 4 ° C and 10 ⁇ l CETP at 37 ° C.
- the activity transferred in the control mixtures with CETP at 37 ° C is rated as 100% transmission.
- the substance concentration at which this transfer is reduced by half is given as the IC 50 value.
- T2 second time
- an appropriate control group is used for each time point, ie 1, 3 or 6 h, whose animals only receive the formulating agent without substance.
- the two blood withdrawals per animal are the same as for the substance-treated animals in order to determine the change in CETP activity without inhibitor over the corresponding experimental period (1, 3 or 6 h).
- the blood samples are centrifuged at the end of the coagulation and the serum is pipetted off.
- CETP fluoride test To determine the CETP activity, the cholesteryl ester transport over 4 h is determined. For this purpose, 2 ⁇ l of serum are generally used in the test batch, and the test is carried out as described under "CETP fluoride test".
- cholesteryl ester transport (pM CE * / h (T2) - pM CE * / h (Tl)) are calculated for each animal and averaged in the groups. A substance that reduces> 30% cholesteryl ester transport at any one time is considered to be effective.
- DMSO dissolved and 0.5% Tylose suspended orally administered by gavage are administered perorally by means of a gavage.
- the control animals receive identical volumes of solvent without test substance. Subsequently, the animals are deprived of food and taken at different times - up to 24 hours after substance application - by puncture of the retroorbital venous plexus blood.
- the determination of the content of HDL cholesterol is carried out after precipitation of the ApoB-containing lipoproteins by means of a reagent mixture (Sigma 352-4 HDL cholesterol reagent) according to the manufacturer.
- transgenic mice In experiments to determine the oral effect on lipoproteins and triglycerides, transgenic mice (Dinchuck, Hart, Gonzalez, Karmann, Schmidt, Wirak; BBA (1995), 1295, 301) test substance are administered by gavage. Before the start of the experiment, the mice are bled retro-orbitally to determine serum cholesterol and triglycerides. The serum is recovered as described above for hamsters by incubation at 4 ° C overnight and subsequent centrifugation at 6000 x g. After one week, the mice are bled again to determine lipoproteins and triglycerides. The changes in the measured parameters are expressed as a percentage change from baseline.
- PE / EE petroleum ether / ethyl acetate
- the measured LC-MS values were determined by the following methods:
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2003532059A JP2005508341A (ja) | 2001-10-01 | 2002-09-18 | 3−ヒドロキシ−(4−トリフルオロメチルフェニル)−メチル−7−スピロシクロブチル−5,6,7,8−テトラヒドロキノリン−5−オール誘導体およびコレステロールエステル転送タンパク質(cetp)阻害剤としてのその使用 |
US10/491,465 US20050043341A1 (en) | 2001-10-01 | 2002-09-18 | 3-'Hydroxy-(-4-trifluoromethylphenyl)-methyl-7-spirocyclobutyl-5,6,7 8-tetrahydroquinolin-5-ol derivatives and the use of the same as cholesterol ester transfer protein (cetp) inhibitors |
EP02772317A EP1434581A1 (de) | 2001-10-01 | 2002-09-18 | 3-[hydroxy-(4-trifluoromethylphenyl)-methyl]-7-spirocyclobutyl-5,6,7,8-tetrahydrochinolin-5-ol- derivate und ihre verwendung als cholesterin-ester-transfer-protein (cetp) - inhibitoren |
CA002462030A CA2462030A1 (en) | 2001-10-01 | 2002-09-18 | 3-`hydroxy-(-4-trifluoromethylphenyl)-methyl-7-spirocyclobutyl-5,6,7,8-tetrahydroquinolin-5-ol derivatives and the use of the same as cholesterol ester transfer protein (cetp) inhibitors |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE10148436A DE10148436A1 (de) | 2001-10-01 | 2001-10-01 | Tetrahydrochinoline |
DE10148436.4 | 2001-10-01 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2003028727A1 WO2003028727A1 (de) | 2003-04-10 |
WO2003028727A9 true WO2003028727A9 (de) | 2003-11-13 |
Family
ID=7701007
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2002/010444 WO2003028727A1 (de) | 2001-10-01 | 2002-09-18 | 3-`hydroxy- (-4-trifluoromethylphenyl) -methyl!-7-spirocyclobutyl-5,6,7,8- tetrahydrochinolin-5-ol-derivate und ihre verwendung als cholesterin-ester-transfer-protein (cetp) - inhibitoren |
Country Status (12)
Country | Link |
---|---|
US (1) | US20050043341A1 (de) |
EP (1) | EP1434581A1 (de) |
JP (1) | JP2005508341A (de) |
AR (1) | AR036583A1 (de) |
CA (1) | CA2462030A1 (de) |
DE (1) | DE10148436A1 (de) |
DO (1) | DOP2002000457A (de) |
GT (1) | GT200200195A (de) |
HN (1) | HN2002000278A (de) |
PE (1) | PE20030604A1 (de) |
UY (1) | UY27458A1 (de) |
WO (1) | WO2003028727A1 (de) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BRPI0414822A (pt) * | 2003-09-26 | 2006-11-14 | Japan Tobacco Inc | método de inibir a produção de lipoproteìna remanescente |
EP1670768B1 (de) | 2003-10-08 | 2009-09-09 | Eli Lilly And Company | Verbindungen und verfahren zur behandlung von dyslipidemie |
JP2007530550A (ja) | 2004-03-26 | 2007-11-01 | イーライ リリー アンド カンパニー | 異脂肪血症を治療するための化合物および方法 |
KR20070090192A (ko) * | 2004-12-18 | 2007-09-05 | 바이엘 헬스케어 아게 | (5s)-3-[(s)-플루오로(4-트리플루오로메틸페닐)메틸]-5,6,7,8-테트라히드로퀴놀린-5-올 유도체 및 이의 cetp억제제로서의 용도 |
US8124775B2 (en) * | 2004-12-18 | 2012-02-28 | Bayer Pharma Aktiengesellschaft | Chemical compound and its use |
DE102006012548A1 (de) | 2006-03-18 | 2007-09-20 | Bayer Healthcare Ag | Substituierte Chromanol-Derivate und ihre Verwendung |
CN101096363B (zh) | 2006-06-27 | 2011-05-11 | 中国人民解放军军事医学科学院毒物药物研究所 | 2,4,5-三取代噻唑类化合物、其制备方法、药物组合物及其制药用途 |
US20080145498A1 (en) * | 2006-12-14 | 2008-06-19 | Kraft Foods Holdings, Inc. | Texture and shape control process for acidified food products |
PL2268644T3 (pl) | 2008-03-05 | 2012-01-31 | Boehringer Ingelheim Int | Tricykliczne pochodne piperydyny, leki zawierające te związki, ich zastosowanie i sposoby ich wytwarzania |
JP5780528B2 (ja) * | 2010-02-19 | 2015-09-16 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 三環式ピリジン誘導体、このような化合物を含有する医薬、それらの使用、およびそれらの調製方法 |
TWI506025B (zh) | 2010-07-09 | 2015-11-01 | Daiichi Sankyo Co Ltd | 取代吡啶化合物 |
US9150583B2 (en) | 2011-08-17 | 2015-10-06 | Boehringer Ingelheim International Gmbh | Furo[3,4-c]quinoline derivatives, medicaments containing such compounds, their use and process for their preparation |
EP2801574B1 (de) * | 2012-01-06 | 2016-07-27 | Daiichi Sankyo Company, Limited | Säureadditionssalze einer substituierten pyridinverbindung als cholesteryl-ester-transfer-protein (cetp) inhibitoren |
EP3191441B1 (de) * | 2014-09-09 | 2020-02-19 | Boehringer Ingelheim International Trading (Shanghai) Co. Ltd. | Neuartiges verfahren zur herstellung von spiro[2,5]octan-5,7-dion und spiro[3,5]nonan-6,8-dion |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HRP970330B1 (en) * | 1996-07-08 | 2004-06-30 | Bayer Ag | Cycloalkano pyridines |
MA24643A1 (fr) * | 1997-09-18 | 1999-04-01 | Bayer Ag | Tetrahydro-naphtalenes substitues et composes analogues |
DE19741051A1 (de) * | 1997-09-18 | 1999-03-25 | Bayer Ag | Hetero-Tetrahydrochinoline |
DE19741399A1 (de) * | 1997-09-19 | 1999-03-25 | Bayer Ag | Tetrahydrochinoline |
-
2001
- 2001-10-01 DE DE10148436A patent/DE10148436A1/de not_active Withdrawn
-
2002
- 2002-09-02 DO DO2002000457A patent/DOP2002000457A/es unknown
- 2002-09-18 CA CA002462030A patent/CA2462030A1/en not_active Abandoned
- 2002-09-18 JP JP2003532059A patent/JP2005508341A/ja active Pending
- 2002-09-18 US US10/491,465 patent/US20050043341A1/en not_active Abandoned
- 2002-09-18 EP EP02772317A patent/EP1434581A1/de not_active Withdrawn
- 2002-09-18 WO PCT/EP2002/010444 patent/WO2003028727A1/de active Application Filing
- 2002-09-25 AR ARP020103608A patent/AR036583A1/es unknown
- 2002-09-27 GT GT200200195A patent/GT200200195A/es unknown
- 2002-09-27 UY UY27458A patent/UY27458A1/es not_active Application Discontinuation
- 2002-09-30 PE PE2002000962A patent/PE20030604A1/es not_active Application Discontinuation
- 2002-10-01 HN HN2002000278A patent/HN2002000278A/es unknown
Also Published As
Publication number | Publication date |
---|---|
AR036583A1 (es) | 2004-09-15 |
HN2002000278A (es) | 2002-12-20 |
EP1434581A1 (de) | 2004-07-07 |
PE20030604A1 (es) | 2003-09-07 |
WO2003028727A1 (de) | 2003-04-10 |
CA2462030A1 (en) | 2003-04-10 |
JP2005508341A (ja) | 2005-03-31 |
UY27458A1 (es) | 2003-04-30 |
DE10148436A1 (de) | 2003-04-17 |
US20050043341A1 (en) | 2005-02-24 |
DOP2002000457A (es) | 2003-04-15 |
GT200200195A (es) | 2003-08-22 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0818448B1 (de) | Cycloalkano-pyridine als CETP-Inhibitoren | |
EP0818197B1 (de) | Heterocyclisch kondensierte Pyridine als CETP Inhibitoren | |
EP1017659B1 (de) | Substituierte tetrahydro-naphtaline und analoge verbindungen | |
EP0796846B1 (de) | 2-Aryl-substituierte Pyridine | |
EP1017692B1 (de) | 4-heteroaryl-tetrahydrochinoline und ihre verwendung als inhibitoren des cholesterin-ester-transfer-proteins (ctep) | |
WO1998039299A1 (de) | 5-oxysubstituierte chinoline und ihre verwendung als inhibitoren des cholesterin-ester-transfer-proteins (ctep) | |
EP1017677A1 (de) | 4-phenyltetrahydrochinoline als hemmer des cholesterolestertransferproteins | |
EP0825185A1 (de) | Bicyclisch kondensierte Pyridine | |
WO2003028727A9 (de) | 3-`hydroxy- (-4-trifluoromethylphenyl) -methyl!-7-spirocyclobutyl-5,6,7,8- tetrahydrochinolin-5-ol-derivate und ihre verwendung als cholesterin-ester-transfer-protein (cetp) - inhibitoren | |
WO2006072362A1 (de) | (5s) - 3 - [(s)-fluor (4-trifluoromethylphenyl) methyl] -5,6,7,8-tetrahydrochinolin-5-ol derivative und ihre verwendung als cetp-inhibitoren | |
EP1828137B1 (de) | 4-cycloalkyl-substituierte tetrahydrochinolinderivate und deren verwendung als medikamente | |
EP1017658A1 (de) | Benzyl-biphenyle und analoge verbindungen und deren verwendung zur behandlung von arteriosklerose und diylipidämien | |
EP0968162A1 (de) | 5-hydroxy-alkyl substituierte phenyle und deren verwendung in arzneimitteln zur behandlung von arteriosklerose und hyperlipoproteinemie | |
WO1998034920A1 (de) | 2-amino-substituierte pyridine verwendbar zur behandlung von arteriosklerose und hyperlipoproteinemie | |
DE19832159A1 (de) | Substituierte Tetrahydro-naphthaline | |
DE102004061001A1 (de) | Chemische Verbindung und ihre Verwendung | |
DE102004060997A1 (de) | Chemische Verbindung und ihre Verwendung | |
DE102004061002A1 (de) | Chemische Verbindung und ihre Verwendung | |
DE102004060998A1 (de) | Chemische Verbindung und ihre Verwendung | |
DE102004061003A1 (de) | Chemische Verbindung und ihre Verwendung | |
DE102004060999A1 (de) | Chemische Verbindung und ihre Verwendung | |
DE102004061000A1 (de) | Chemische Verbindung und ihre Verwendung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BY BZ CA CH CN CO CR CU CZ DE DM DZ EC EE ES FI GB GD GE GH HR HU ID IL IN IS JP KE KG KP KR LC LK LR LS LT LU LV MA MD MG MN MW MX MZ NO NZ OM PH PL PT RU SD SE SG SI SK SL TJ TM TN TR TZ UA UG US UZ VC VN YU ZA ZM |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ UG ZM ZW AM AZ BY KG KZ RU TJ TM AT BE BG CH CY CZ DK EE ES FI FR GB GR IE IT LU MC PT SE SK TR BF BJ CF CG CI GA GN GQ GW ML MR NE SN TD TG AE AG AL AM AT AZ BA BB BG BR BY BZ CA CH CN CO CR CZ DE DK DM DZ EC EE ES FI GB GD GE GM HR HU ID IL IN IS JP KE KG KP KR KZ LK LR LS LT LU LV MA MD MG MK MN MX MZ NO NZ OM PH PL PT RO RU SD SE SI SK SL TJ TM TN TR TT TZ UA UG UZ VC YU ZA ZM ZW GH GM KE LS MW MZ SL SZ TZ UG ZM ZW |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
COP | Corrected version of pamphlet |
Free format text: PUBLISHED INTERNATIONAL SEARCH REPORT (6 PAGES) REPLACED BY CORRECT INTERNATIONAL SEARCH REPORT (6PAGES) |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2002772317 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2462030 Country of ref document: CA |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003532059 Country of ref document: JP |
|
WWP | Wipo information: published in national office |
Ref document number: 2002772317 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWE | Wipo information: entry into national phase |
Ref document number: 10491465 Country of ref document: US |